2019: KEI comments on NIH prospective license to Morphiex on CD47 for solid tumors (and NIH Response)
(UPDATE: The NIH provided a response to our comments on April 22, 2019) On February 20, 2019, KEI submitted comments to the Federal Register notice 84 FR 1764 on the “Prospective Grant of an Exclusive Patent License: Use of the… Continue Reading